Sriram Sundaravel

Sriram Sundaravel

Auto-generated profile, based on publicly available information

Sriram Sundaravel

Albert Einstein College of Medicine 1 Department of Cell Biology Bronx, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RPRichard T. Piszczatowski
Richard T. Piszczatowski
ESEmily Schwenger
Emily Schwenger
SSSriram Sundaravel
Sriram Sundaravel
CSCatarina M. Stein
Catarina M. Stein
YLYang Liu
Yang Liu
USUlrich Steidl
Ulrich Steidl
Cell surfaces display a wide array of molecules that confer identity. While flow cytometry and cluster of differentiation (CD) markers have revolutionized cell characterization and purification, functionally heterogeneous cellular subtypes remain unresolvable by the CD marker system alone. Using hematopoietic lineages as a paradigm, we leverage the extraordinary molecular diversity of heparan sulfate (HS) glycans to establish cellular “glycotypes” by utilizing a panel of anti-HS single-chain variable fragment antibodies (scFvs). Prospective sorting with anti-HS scFvs identifies functionally distinct glycotypes within heterogeneous pools of mouse and human hematopoietic progenitor cells and enables further stratification of immunophenotypically pure megakaryocyte–erythrocyte progenitors. This stratification correlates with expression of a heptad of HS-related genes that is reflective of the HS epitope recognized by specific anti-HS scFvs. While we show that HS glycotyping provides an orthogonal set of tools for resolution of hematopoietic lineages, we anticipate broad utility of this approach in defining and isolating novel, viable cell types across diverse tissues and species.

1 July 2026
Verified
Other
Open access
GTGoichi Tatsumi
Goichi Tatsumi
RKRajni Kumari
Rajni Kumari
YSYutaro Suzuki
Yutaro Suzuki
SLShuting Li
Shuting Li
RSRussell Scharf
Russell Scharf
USUlrich Steidl
Ulrich Steidl
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance.Significance:This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.

1 July 2026
Verified
Other
Open access
GTGoichi Tatsumi
Goichi Tatsumi
RKRajni Kumari
Rajni Kumari
YSYutaro Suzuki
Yutaro Suzuki
SLShuting Li
Shuting Li
RSRussell Scharf
Russell Scharf
USUlrich Steidl
Ulrich Steidl
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

18 May 2026 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
GTGoichi Tatsumi
Goichi Tatsumi
RKRajni Kumari
Rajni Kumari
YSYutaro Suzuki
Yutaro Suzuki
SLShuting Li
Shuting Li
RSRussell Scharf
Russell Scharf
USUlrich Steidl
Ulrich Steidl
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.

1 July 2026
Verified
Other
Open access
PDF file
GTGoichi Tatsumi
Goichi Tatsumi
RKRajni Kumari
Rajni Kumari
YSYutaro Suzuki
Yutaro Suzuki
SLShuting Li
Shuting Li
RSRussell Scharf
Russell Scharf
USUlrich Steidl
Ulrich Steidl
Figure S1. The effects of short-term AraC treatment on RNA transcription dynamics and AraC resistance acquisition. Figure S2.Absence of genetic clonal selection in rapid AraC resistance development. Figure S3. Suppression of RNA induction interferes with the acquisition of AraC resistance in NB4 and MOLM14. Figure S4. Transcriptomic profiling identifies key role of AraC-rapid response TFs (ARRTFs) in acquisition of drug resistance. Figure S5. Not all hematopoiesis-related TFs are transcriptionally activated following AraC treatment. Figure S6. Transcription dynamics after AraC treatment inNB4. Figure S7. Modest changes in chromatin accessibility (detected by ATACseq) during the development of rapidAraC drug resistance. Figure S8. Flow cytometry gating strategy for analyzing RNA dynamics in hematopoietic stem and progenitor cells (HSPCs) of AMLpatient samples. Figure S9. Evaluation of cell proliferation of control and TF-KO subclones in steady state.

1 July 2026
Verified
Other
Open access
GTGoichi Tatsumi
Goichi Tatsumi
RKRajni Kumari
Rajni Kumari
YSYutaro Suzuki
Yutaro Suzuki
SLShuting Li
Shuting Li
RSRussell Scharf
Russell Scharf
USUlrich Steidl
Ulrich Steidl
Table 1: Key Reagents & Resources. Table 2: WES. Table 3: Primers and sgRNAs. Table 4: GSEA. Table 5: SmFISH probes. Table 6: Patient samples.